MX2021013101A - Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. - Google Patents

Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.

Info

Publication number
MX2021013101A
MX2021013101A MX2021013101A MX2021013101A MX2021013101A MX 2021013101 A MX2021013101 A MX 2021013101A MX 2021013101 A MX2021013101 A MX 2021013101A MX 2021013101 A MX2021013101 A MX 2021013101A MX 2021013101 A MX2021013101 A MX 2021013101A
Authority
MX
Mexico
Prior art keywords
patients
cells
therapy
limited number
antibodies
Prior art date
Application number
MX2021013101A
Other languages
English (en)
Spanish (es)
Inventor
Jan Endell
Mark Winderlich
Christian Kuffer
Günter Fingerle-Rowson
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2021013101A publication Critical patent/MX2021013101A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013101A 2019-05-03 2020-05-04 Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. MX2021013101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19172495 2019-05-03
PCT/EP2020/062289 WO2020225196A1 (en) 2019-05-03 2020-05-04 Anti-cd19 therapy in patients having a limited number of nk cells

Publications (1)

Publication Number Publication Date
MX2021013101A true MX2021013101A (es) 2022-01-04

Family

ID=66647010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013101A MX2021013101A (es) 2019-05-03 2020-05-04 Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.

Country Status (15)

Country Link
US (1) US20220242952A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962943A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022532519A (cg-RX-API-DMAC7.html)
KR (1) KR20220007087A (cg-RX-API-DMAC7.html)
CN (1) CN114072424A (cg-RX-API-DMAC7.html)
AU (1) AU2020267823A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137664A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193024A1 (cg-RX-API-DMAC7.html)
IL (1) IL287203A (cg-RX-API-DMAC7.html)
MA (1) MA55794A (cg-RX-API-DMAC7.html)
MX (1) MX2021013101A (cg-RX-API-DMAC7.html)
MY (1) MY209449A (cg-RX-API-DMAC7.html)
PH (1) PH12021552743A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111343TA (cg-RX-API-DMAC7.html)
WO (1) WO2020225196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2021084062A1 (en) * 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes

Also Published As

Publication number Publication date
PH12021552743A1 (en) 2022-07-11
MA55794A (fr) 2022-03-09
CA3137664A1 (en) 2020-11-12
US20220242952A1 (en) 2022-08-04
EA202193024A1 (ru) 2022-02-09
CN114072424A (zh) 2022-02-18
EP3962943A1 (en) 2022-03-09
MY209449A (en) 2025-07-09
JP2026004466A (ja) 2026-01-14
WO2020225196A1 (en) 2020-11-12
IL287203A (en) 2021-12-01
SG11202111343TA (en) 2021-11-29
AU2020267823A1 (en) 2021-11-11
JP2022532519A (ja) 2022-07-15
KR20220007087A (ko) 2022-01-18

Similar Documents

Publication Publication Date Title
PH12021552743A1 (en) Anti-cd19 therapy in patients having a limited number of nk cells
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
MX2025002661A (es) Composiciones anti-cd24 y usos de las mismas
MX2021005734A (es) Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b.
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
MY187247A (en) Low density polishing pad
ES2571235T3 (es) Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
ECSP22094536A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
ZA202100296B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
MY194175A (en) Variant rnai
ECSP13012597A (es) Agentes de unión a CD33
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
CR20200361A (es) Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof
BR112022012885A2 (pt) Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit
MX2023013228A (es) Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax.
MX2021007488A (es) Uso de anticuerpos il-1 beta en el tratamiento o prevencion del sindrome mielodisplasico.
BR112022007216A2 (pt) Métodos para tratamento de linfoma difuso, kit e imunoconjugado
CL2023000476A1 (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d de complemento
MX2021008686A (es) Tratamiento del linfoma de linfocitos t.
CL2020003169A1 (es) Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia